Hepatitis C Archives - Infectious Disease Advisor

sexually transmitted diseases, clipboard, pills, STDs

STI Testing and Prevention Services Trends Among Men

By

Zahra Masoud

May 22, 2020

Men who have sex with men are more likely to receive the recommended sexually transmitted infection testing and prevention services at Ryan White HIV/AIDS Program-funded facilities.

Hepatitis

Opt-Out Universal Hep C Screening in Emergency Dept Is Useful

May 20, 2020

Emergency department opt-out universal hepatitis C virus (HCV) screening can identify a large number of unrecognized HCV infections.

Hepatitis

Infective Endocarditis Rates Markedly Increased in Young People With HCV, Opioid Use Disorder

By

Sweta Gupta

April 27, 2020

In parallel to the ongoing national opioid crisis, the incidence rate of infective endocarditis cases has increased markedly among people aged 18 to 29 years with hepatitis C virus infection and those with opioid use disorder.

PCT manifests when hepatic UROD activity is <20% of normal.1 As porphyrins accumulate in the liver, they are transported to the skin, leading to phototoxicity as light exposure causes the porphyrins to release photons.1 Subsequently, patients develop blisters on sun-exposed areas of their skin, particularly the hands, face, neck, and forearms. These areas are also prone to blisters and peeling after mild trauma. When the lesions scar, they may resemble systemic scleroderma. In some cases, lesions become painful. Patients may also have abnormal hair growth, skin thickening, and hypopigmentation. PCT is diagnosed when elevated porphyrins are detected in the plasma. Urine and fecal studies can confirm the diagnosis when they show similarly elevated porphyrin levels, with urine typically showing excess uroporphyrin and 7-carboxylate porphyrin and feces showing excess isocoproporphyrin.6 Patients with a PCT diagnosis should be tested for HCV if their status is unknown. Photo Credit: Dr Harout Tanielian/Science Source.

Hepatitis

Effects of Sustained Virologic Response to HCV Therapy on Autoimmune Disease Incidence

By

Bradley van Paridon

April 16, 2020

Patients with chronic hepatitis C (HCV) achieving sustained virologic response to pegylated interferon plus ribavirin therapy did not exhibit an effect on the incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis.

Hepatitis

Hydromorphone Controlled-Release Dispensing Rates May Predict HCV Incidence

By

Zahra Masoud

April 14, 2020

Compared with all opioid prescriptions, a higher hydromorphone controlled-release dispensing rate was a strong predictor of hepatitis C virus incidence.

Diagnostics

mRECIST Inclusion Improves Metroticket 2.0 Criteria Prediction for Liver Transplantation

By

Zahra Masoud

April 9, 2020

A more accurate prediction for assessing the eligibility of candidates for liver transplantation who received neoadjuvant therapies was shown when mRECIST radiologic response was included within the Metroticket 2.0 framework.

CROI 2020

Raltegravir-Based ART Shows Lower Rates of Hepatoxicity

By

Zahra Masoud

April 3, 2020

Replacing efavirenz (EFV) with raltegravir (RAL) in antiretroviral therapy (ART) may decrease hepatotoxicity in patients who are coinfected with HIV and hepatitis C virus (HCV).

Hepatitis

Phylogenetic Analysis May Assist With HCV Prevention Strategies in PWID

By

Sweta Gupta

April 3, 2020

Next-generation sequencing is an important tool that can help differentiate HCV reinfection from treatment failure, and may assist with the design of targeted prevention strategies in PWID receiving opioid agonist therapy.

CROI 2020

Sofosbuvir/Velpatasvir Combination Therapy Efficacious in HCV/HIV Coinfection

By

Infectious Disease Advisor Contributing Writer

March 25, 2020

Combination sofosbuvir/velpatasvir treatment can be highly efficacious in treating hepatitis C virus (HCV) infection in patients coinfected with HIV.

CROI 2020

Transmission of DAA Resistance Inhibits Cure Rates Among HIV/HCV Coinfected MSM

By

Dibash Das, PhD

March 24, 2020

The transmission of direct-acting antiviral (DAA) resistance-associated substitutions (RAS) may inhibit hepatitis C virus (HCV) cure rates and elimination efforts.